Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States | Zendy

Ismael R. Ortega Sanchez | Zendy; Martin I. Meltzer | Zendy; Colin W. Shepard | Zendy; Elizabeth R. Zell | Zendy; Mark L. Messonnier | Zendy; Oleg Bilukha | Zendy; Xinzhi Zhang | Zendy; David S. Stephens | Zendy; Nancy E. Messonnier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States

Author(s) -

Ismael R. Ortega Sanchez,

Martin I. Meltzer,

Colin W. Shepard,

Elizabeth R. Zell,

Mark L. Messonnier,

Oleg Bilukha,

Xinzhi Zhang,

David S. Stephens,

Nancy E. Messonnier

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/524041

Subject(s) - medicine , vaccination , herd immunity , meningococcal disease , meningococcal vaccine , immunization , pediatrics , incidence (geometry) , environmental health , demography , neisseria meningitidis , immunology , physics , antigen , sociology , optics , genetics , biology , bacteria

In June 2005, the Advisory Committee on Immunization Practices recommended the newly licensed quadrivalent meningococcal conjugate vaccine for routine use among all US children aged 11 years. A 1-time catch-up vaccination campaign for children and adolescents aged 11-17 years, followed by routine annual immunization of each child aged 11 years, could generate immediate herd immunity benefits. The objective of our study was to analyze the cost-effectiveness of a catch-up vaccination campaign with quadrivalent meningococcal conjugate vaccine for children and adolescents aged 11-17 years.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research